Find clinical trials for Triple Negative Breast Cancer in Cleveland, OH
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Triple Negative Breast Cancer trials near Cleveland, OH, USA:
This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specif-...
Phase 2
Cleveland, Ohio, United States and 5 other locations
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...
Phase 2
Cleveland, Ohio, United States and 13 other locations
with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...
Phase 3
Cleveland, Ohio, United States and 360 other locations
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...
Phase 3
Cleveland, Ohio, United States and 288 other locations
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...
Phase 1
Cleveland, Ohio, United States and 23 other locations
(HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative...
Phase 1
Cleveland, Ohio, United States and 52 other locations
phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors....
Phase 1
Cleveland, Ohio, United States and 6 other locations
The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standa...
Phase 1
Cleveland, Ohio, United States and 13 other locations
tumors....
Phase 1
Cleveland, Ohio, United States and 7 other locations
study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor...
Phase 1
Cleveland, Ohio, United States and 23 other locations
Clinical trials
Research sites
Resources
Legal